pepmg_

Study summary · research use only

Humanin and the receptors for humanin

Review · human · Molecular neurobiology · 2010 · DOI 10.1007/s12035-009-8090-z · PMID 19997871

Plain-language summary

Paraphrased from the published abstract below — not a verdict on whether anything works.

This review discusses Humanin and its receptors in the context of Alzheimer's disease (AD). The authors describe AD as a prevalent dementia-causing neurodegenerative disease in which neuronal death is closely linked to progression of dementia, and state that accumulating evidence has established that a 24-amino-acid bioactive peptide, Humanin, protects neurons from AD-related neuronal death. They report that studies using various murine AD models, including familial-AD-gene-expressing transgenic mice, have shown Humanin to be active against AD-related neuronal dysfunction in vivo, and that Humanin was shown to inhibit neuronal cell death and dysfunction by binding a novel IL-6-receptor-related receptor involving CNTFRalpha, WSX-1, and gp130. The authors suggest that endogenous Humanin or a Humanin-like substance may suppress the onset of AD-related dementia by inhibiting both AD-related neuronal death and dysfunction.

Abstract

Alzheimer's disease (AD) is a prevalent dementia-causing neurodegenerative disease. Neuronal death is closely linked to the progression of AD-associated dementia. Accumulating evidence has established that a 24-amino-acid bioactive peptide, Humanin, protects neurons from AD-related neuronal death. A series of studies using various murine AD models including familial AD gene-expressing transgenic mice have shown that Humanin is effective against AD-related neuronal dysfunction in vivo. Most recently, it has been shown that Humanin inhibits neuronal cell death and dysfunction by binding to a novel IL-6-receptor-related receptor(s) on the cell surface involving CNTFRalpha, WSX-1, and gp130. These findings suggest that endogenous Humanin [or a Humanin-like substance(s)] may suppress the onset of AD-related dementia by inhibiting both AD-related neuronal cell death and dysfunction.

Read the full study on PubMed ↗

pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.